Article

Study: Intranasal Glucagon Effective Alternative to Shots in Kids with Type 1 Diabetes

Author(s):

Injecting pediatric diabetes type 1 patients with glucagon can be difficult for non-medical caregivers. Such treatment is needed for severe hypoglycemia. A new study shows that an inhaled glucagon powder is effective and easier on these rescuers.

Intranasal glucagon powder treatment for diabetes type 1 emergencies showed a much higher success rate with fewer errors than injection with commercially available glucagon, researchers reported. The treatment is meant to reverse insulin-induced hypoglycemia in these patients. In glucagon is absorbed, not inhaled.

In an abstract presented at the 51st Annual Meeting of the European Association for the Study of Diabetes (EASD) Jennifer Sherr, MD, PhD of Yale School of Medicine said her study showed that glucagon nasal powder (GNP/Locemia Solutions) was faster to administer and resulted in blood sugar response equivalent to that of the standard injection.

In her study, the nasal glucagon is being evaluated for pediatric patients ages 4 to 17 with diabetes type 1.

Other than the case of one six-year-old participant who blew his nose before the powder was absorbed, the results were favorable and there were no major side effects.

In a related study evaluating the powder's use in adults,subjects acting as caregivers delivered the treatment to mannequins.

The lead investigator was Jean-Francois Yale, M D, of McGill University in Montreal, Canada.

As part of the study they had to find the glucagon kit--either the powder or a standard injection kit--in the mannequin's backpack. The researchers used distracting sound effects to simulate a real-life situation.

The subjects did not do well, overall. Though some completed the task successfully, one subject refused to do the injection, others injected only the dilutant, and one injected insulin instead of glucagon.

As the Canada study showed, current injection kits can be intimidating for non-medical caregivers called on to deal with an episode of severe hypoglycemia.

Using these kits means following a multi-step process to reconstitute the glucagon solution, in addition to the anxiety the rescuer may have about giving an injection, the researchers said.

Editor's Note: The glucagon is absorbed, not inhaled, as incorrectly stated in an earlier version of this story.

Related Videos
Alice Cheng, MD: Exploring the Link Between Diabetes and Dementia | Image Credit: LinkedIn
Jennifer B. Green, MD: Implementation of Evidence-Based Therapies for T2D | Image Credit: Duke University
Ralph A. DeFronzo, MD: Noxious Nine and Mifepristone for Hypercortisolism in T2D | Image Credit: LinkedIn
Diabetes Dialogue: Diabetes Tech Updates from November 2024 | Image Credit: HCPLive
Viet Le, DMSc, PA-C | Credit: APAC
Diabetes Dialogue: Tirzepatide’s Long-Term Obesity Data | Image Credit: HCPLive
Diabetes Dialogue: Latest Updates on Semaglutide Shortage, Data | Image Credit: HCPLive
HCPLive CKD and CVD NewsNetwork Thumbnail
HCPLive CKD and CVD NewsNetwork Thumbnail
HCPLive CKD and CVD NewsNetwork Thumbnail
© 2024 MJH Life Sciences

All rights reserved.